Evidence map›Paper›PMID 35088050›Full record

ArticleNeuro-oncology advances

GammaTile® brachytherapy in the treatment of recurrent glioblastomas.

Dominic J Gessler, Elizabeth C Neil, Rena Shah, Joseph Levine, James Shanks, Christopher Wilke, Margaret Reynolds, Shunqing Zhang, Can Özütemiz, Mehmet Gencturk and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Trial
  2. GammaTileCancers · 2026
    Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. GammaTileJournal of neuro-oncology · 2024
    Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Dominic J GesslerDepartment of Neurosurgery, University of Minnesota, Minneapolis, Minnesota, USA.ORCID https://orcid.org/0000-0003-0067-7444
Elizabeth C NeilDepartment of Neurology, University of Minnesota, Minneapolis, Minnesota, USA.
Rena ShahDepartment of Oncology, North Memorial Health, Robbinsdale, Minnesota, USA.
Joseph LevineDepartment of Oncology, North Memorial Health, Robbinsdale, Minnesota, USA.
James ShanksDepartment of Oncology, Fairview Cancer Care, Minneapolis, Minnesota, USA.
Christopher WilkeDepartment of Radiation Oncology, University of Minnesota, Minneapolis, Minnesota, USA.
Margaret ReynoldsDepartment of Radiation Oncology, University of Minnesota, Minneapolis, Minnesota, USA.
Shunqing ZhangDepartment of Radiation Oncology, University of Minnesota, Minneapolis, Minnesota, USA.
Can ÖzütemizDepartment of Radiology, University of Minnesota, Minneapolis, Minnesota, USA.
Mehmet GencturkDepartment of Radiology, University of Minnesota, Minneapolis, Minnesota, USA.
Mark FolkertsmaDepartment of Radiology, University of Minnesota, Minneapolis, Minnesota, USA.
W Robert BellDepartment of Pathology, University of Minnesota, Minneapolis, Minnesota, USA.
Liam ChenDepartment of Pathology, University of Minnesota, Minneapolis, Minnesota, USA.
Clara FerreiraDepartment of Radiation Oncology, University of Minnesota, Minneapolis, Minnesota, USA.
Kathryn DusenberyDepartment of Radiation Oncology, University of Minnesota, Minneapolis, Minnesota, USA.
Clark C ChenDepartment of Neurosurgery, University of Minnesota, Minneapolis, Minnesota, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGammaTile® (GT) is a recent U.S. Food and Drug Administration (FDA) cleared brachytherapy platform. Here, we report clinical outcomes for recurrent glioblastoma patients after GT treatment following maximal safe resection.

methodsWe prospectively followed twenty-two consecutive Isocitrate Dehydrogenase (IDH) wild-type glioblastoma patients (6 O

resultsThe cohort consisted of 14 second and eight third recurrences. In terms of procedural safety, there was one 30-day re-admission (4.5%) for an incisional cerebrospinal fluid leak, which resolved with lumbar drainage. No other wound complications were observed. Six patients (27.2%) declined in Karnofsky Performance Score (KPS) after surgery due to worsening existing deficits. One patient suffered a new-onset seizure postsurgery (4.5%). There was one (4.5%) 30-day mortality from intracranial hemorrhage secondary to heparinization for an ischemic limb. The mean follow-up was 733 days (range 279-1775) from the time of initial diagnosis. Six-month local control (LC

conclusionsThis clinical experience supports GT brachytherapy as a treatment option in a multi-modality treatment strategy for recurrent glioblastomas.

Indexed as

brachytherapyGammaTile®O6-Methylguanine-DNA methyltransferase (MGMT)recurrent glioblastoma

Identifiers

PMID35088050
PMCPMC8788013

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.